Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance

DNA Repair

Volumn 54, Issue , 2017, Pages 13-21

  Jeddi, Farhad ^a,b   Soozangar, Narges ^a,b   Sadeghi, Mohammad Reza ^a,b   Somi, Mohammad Hossein ^a,b   Samadi, Nasser ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemoresistance; Detoxification; Keap1; Nrf2; Oxidative stress

Indexed keywords

ALDO KETO REDUCTASE; ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; OXIDOREDUCTASE; PEROXIREDOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIOREDOXIN 1; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CANCER RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION; ANIMAL; DRUG RESISTANCE; METABOLISM; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85017455586     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2017.03.008     Document Type: Review

References (203)

1. [1] Loignon, M., et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol. Cancer Ther. 8:8 (2009), 2432–2440.
2. [2] Siegel, D., Ross, D., Immunodetection of NAD (P) H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic. Biol. Med. 29:3 (2000), 246–253.
3. [3] Basu, S., et al. Immunohistochemical analysis of NAD (P) H: quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int. J. Cancer 109:5 (2004), 703–709.
4. [4] Homma, S., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 15:10 (2009), 3423–3432.
5. [5] Mishra, M., Zhong, Q., Kowluru, R.A., Epigenetic modifications of keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci., 55(11), 2014, 7256.
6. [6] Villeneuve, N.F., Lau, A., Zhang, D.D., Regulation of the Nrf2–Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid. Redox Signal. 13:11 (2010), 1699–1712.
7. [7] Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2–Keap1 signaling pathway in cancer. Genes Dev. 27:20 (2013), 2179–2191.
8. [8] Shelton, P., Jaiswal, A.K., The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?. FASEB J. 27:2 (2013), 414–423.
9. [9] Taguchi, K., Motohashi, H., Yamamoto, M., Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells 16:2 (2011), 123–140.
10. [10] Schafer, M., et al. Nrf2: a central regulator of UV protection in the epidermis. Cell Cycle 9:15 (2010), 2917–2918.
11. [11] Beyer, T.A., Werner, S., The cytoprotective Nrf2 transcription factor controls insulin receptor signaling in the regenerating liver. Cell Cycle 7:7 (2008), 874–878.
12. [12] Beyer, T.A., et al. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J. 27:1 (2008), 212–223.
13. [13] Brigelius-Flohé, R., et al. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int. J. Cell Biol., 2012, 2012.
14. [14] Eades, G., et al. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J. Biol. Chem. 286:47 (2011), 40725–40733.
15. [15] Yokoo, Y., et al. Effects of Nrf2 silencing on oxidative stress-associated intestinal carcinogenesis in mice. Cancer Med., 2016.
16. [16] Iida, K., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 64:18 (2004), 6424–6431.
17. [17] Khor, T.O., et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prevent. Res. 1:3 (2008), 187–191.
18. [18] Zhang, P., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9:2 (2010), 336–346.
19. [19] Leinonen, H.M., et al. Dysregulation of the Keap1–Nrf2 pathway in cancer. Biochem. Soc. Trans. 43:4 (2015), 645–649.
20. [20] Rushworth, S.A., Bowles, K.M., MacEwan, D.J., High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res. 71:5 (2011), 1999–2009.
21. [21] Pietsch, E.C., et al. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J. Biol. Chem. 278:4 (2003), 2361–2369.
22. [22] Kim, S.K., et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic. Biol. Med. 45:4 (2008), 537–546.
23. [23] Akhdar, H., et al. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur. J. Cancer 45:12 (2009), 2219–2227.
24. [24] Giudice, A., Montella, M., Activation of the Nrf2–ARE signaling pathway: a promising strategy in cancer prevention. Bioessays 28:2 (2006), 169–181.
25. [25] Kwak, M.-K., Kensler, T.W., Targeting NRF2 signaling for cancer chemoprevention. Toxicology and applied pharmacology 244:1 (2010), 66–76.
26. [26] Hayes, J.D., et al. Cancer chemoprevention mechanisms mediated through the Keap1–Nrf2 pathway. Antioxid. Redox Signal. 13:11 (2010), 1713–1748.
27. [27] Slocum, S.L., Kensler, T.W., Nrf2: control of sensitivity to carcinogens. Arch. Toxicol. 85:4 (2011), 273–284.
28. [28] Chan, K., et al. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc. Natl. Acad. Sci. U. S. A. 93:24 (1996), 13943–13948.
29. [29] Geismann, C., et al. Cytoprotection “gone astray”: Nrf2 and its role in cancer. OncoTargets Ther., 7, 2014, 1497.
30. [30] McMahon, M., et al. The Cap ‘n’ Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 61:8 (2001), 3299–3307.
31. [31] Hayes, J., et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans. 28:2 (2000), 33–41.
32. [32] Chanas, S., et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J. 365 (2002), 405–416.
33. [33] Chan, J.Y., Kwong, M., Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta: Gene Struct. Expr. 1517:1 (2000), 19–26.
34. [34] Kwak, M.-K., et al. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol. Med., 7(2), 2001, 135.
35. [35] Schultz, M.A., et al. Nrf1 and nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. PLOS ONE, 9(1), 2014, e87204.
36. [36] Venugopal, R., Jaiswal, A.K., Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD (P) H: quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A. 93:25 (1996), 14960–14965.
37. [37] Kou, X., et al. Natural products for cancer prevention associated with Nrf2–ARE pathway. Food Sci. Hum. Wellness 2:1 (2013), 22–28.
38. [38] Khor, T.O., et al. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 82:9 (2011), 1073–1078.
39. [39] Kumar, H., et al. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat. Prod. Rep. 31:1 (2014), 109–139.
40. [40] Lau, A., et al. Dual roles of Nrf2 in cancer. Pharmacol. Res. 58:5 (2008), 262–270.
41. [41] Geismann, C., et al. Cytoprotection “gone astray”: Nrf2 and its role in cancer. Onco Targets Ther. 7 (2014), 1497–1518.
42. [42] Ramos-Gomez, M., et al. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene–DNA adducts and tumor yield in mice. Carcinogenesis 24:3 (2003), 461–467.
43. [43] Yates, M.S., et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole. Cancer Res. 66:4 (2006), 2488–2494.
44. [44] Satoh, H., et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31:10 (2010), 1833–1843.
45. [45] Menegon, S., Columbano, A., Giordano, S., The dual roles of NRF2 in cancer. Trends Mol. Med., 2016.
46. [46] Ikeda, H., Nishi, S., Sakai, M., Transcription factor Nrf2/MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem. J. 380 (2004), 515–521.
47. [47] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12:8 (2012), 564–571.
48. [48] Gañán-Gómez, I., et al. Oncogenic functions of the transcription factor Nrf2. Free Radic. Biol. Med. 65 (2013), 750–764.
49. [49] Lister, A., et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol. Cancer, 10, 2011, 37.
50. [50] Chen, N., et al. Nrf2 expression in endometrial serous carcinomas and its precancers. Int. J. Clin. Exp. Pathol. 4:1 (2010), 85–96.
51. [51] Yoo, N.J., et al. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60:6 (2012), 943–952.
52. [52] Lei, Z., et al. Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma. BMC Cancer, 16(1), 2016, 410.
53. [53] Shibata, T., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105:36 (2008), 13568–13573.
54. [54] Bryan, H.K., et al. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem. Pharmacol. 85:6 (2013), 705–717.
55. [55] Solis, L.M., et al. Nrf2 and Keap1 abnormalities in non–small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 16:14 (2010), 3743–3753.
56. [56] Wang, R., et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 373:1 (2008), 151–154.
57. [57] Hanada, N., et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer, 12(1), 2012, 66.
58. [58] Barbano, R., et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 8:1 (2013), 105–112.
59. [59] Van Jaarsveld, M., et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32:36 (2013), 4284–4293.
60. [60] Yang, M., et al. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res. Treat. 129:3 (2011), 983–991.
61. [61] Yamamoto, S., et al. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol. Cancer Res. 12:1 (2014), 58–68.
62. [62] Kinch, L., Grishin, N.V., Brugarolas, J., Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 20:4 (2011), 418–420.
63. [63] Ramos, P., Bentires-Alj, M., Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 34:28 (2015), 3617–3626.
64. [64] Szakács, G., et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5:3 (2006), 219–234.
65. [65] Tew, K.D., Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:16 (1994), 4313–4320.
66. [66] Wosikowski, K., et al. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 3:12 (1997), 2405–2414.
67. [67] Rosell, R., et al. Molecular predictors of response to chemotherapy in lung cancer. Seminars in Oncology, 2004, Elsevier.
68. [68] O'Connor, P.M., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:19 (1997), 4285–4300.
69. [69] Borek, C., Antioxidants and radiation therapy. J. Nutr. 134:11 (2004), 3207S–3209S.
70. [70] Zhivotovsky, B., Joseph, B., Orrenius, S., Tumor radiosensitivity and apoptosis. Exp. Cell Res. 248:1 (1999), 10–17.
71. [71] Lee, J.-M., et al. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 278:14 (2003), 12029–12038.
72. [72] Smith, J.A., et al. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother. Pharmacol. 62:1 (2008), 51–58.
73. [73] Meijerman, I., Beijnen, J.H., Schellens, J.H., Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat. Rev. 34:6 (2008), 505–520.
74. [74] Lu, M.C., et al. The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update. Med. Res. Rev., 2016.
75. [75] Shibata, T., et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology, 135(4), 2008 1358.e4–1368.e4.
76. [76] Wang, X.-J., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:6 (2008), 1235–1243.
77. [77] Tarumoto, T., et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp. Hematol. 32:4 (2004), 375–381.
78. [78] Wang, X.J., et al. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic. Biol. Med. 70 (2014), 68–77.
79. [79] Tang, X., et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med. 50:11 (2011), 1599–1609.
80. [80] Chian, S., et al. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac. J. Cancer Prevent. 15:6 (2013), 2911–2916.
81. [81] Sabzichi, M., et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac. J. Cancer Prevent. 15:13 (2014), 5311–5316.
82. [82] Chian, S., et al. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochemical and biophysical research communications 447:4 (2014), 602–608.
83. [83] Verma, A.K., et al. Isoniazid prevents Nrf2 translocation by inhibiting ERK1 phosphorylation and induces oxidative stress and apoptosis. Redox Biol. 6 (2015), 80–92.
84. [84] Wagner, A.E., et al. Ascorbic acid partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in cultured hepatocytes-role of the redox-regulated transcription factor Nrf2. BMC Complement. Altern. Med., 11(1), 2011, 1.
85. [85] Valenzuela, M., et al. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br. J. Cancer 111:5 (2014), 874–882.
86. [86] Ren, D., et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U. S. A. 108:4 (2011), 1433–1438.
87. [87] Olayanju, A., et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radic. Biol. Med. 78 (2015), 202–212.
88. [88] Do, M.T., et al. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic. Biol. Med. 74 (2014), 21–34.
89. [89] Boesch-Saadatmandi, C., et al. Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells. J. Anim. Physiol. Anim. Nutr. 93:5 (2009), 547–554.
90. [90] Arlt, A., et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32:40 (2013), 4825–4835.
91. [91] Zhu, J., et al. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. Free Radic. Biol. Med. 99 (2016), 544–556.
92. [92] MacLeod, A.K., et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 30:9 (2009), 1571–1580.
93. [93] Malhotra, D., et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38:17 (2010), 5718–5734.
94. [94] Singh, A., et al. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol. Cancer Ther. 9:8 (2010), 2365–2376.
95. [95] Wang, X., et al. Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood–brain and blood–spinal cord barriers. J. Neurosci. 34:25 (2014), 8585–8593.
96. [96] Jozkowicz, A., Was, H., Dulak, J., Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signal. 9:12 (2007), 2099–2118.
97. [97] Chau, L.-Y., Heme oxygenase-1: emerging target of cancer therapy. J. Biomed. Sci., 22(1), 2015, 22.
98. [98] Ferrando, M., et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 14:4 (2011), 467–479.
99. [99] Hill, M., et al. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J. 19:14 (2005), 1957–1968.
100. [100] Chao, C.-Y., et al. Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells. Carcinogenesis 34:8 (2013), 1843–1851.
101. [101] Was, H., et al. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol. 169:6 (2006), 2181–2198.
102. [102] Loboda, A., et al. Janus face of Nrf2–HO-1 axis in cancer—Friend in chemoprevention, foe in anticancer therapy. Lung Cancer 60:1 (2008), 1–3.
103. [103] Wang, J., et al. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J. Surg. Res. 164:1 (2010), e99–e105.
104. [104] Bancos, S., et al. Induction of heme oxygenase-1 in normal and malignant B lymphocytes by 15-deoxy-Δ 12,14-prostaglandin J 2 requires Nrf2. Cell. Immunol. 262:1 (2010), 18–27.
105. [105] Kweon, M.-H., et al. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281:44 (2006), 33761–33772.
106. [106] Brigelius-Flohé, R., Selenium compounds and selenoproteins in cancer. Chem. Biodivers. 5:3 (2008), 389–395.
107. [107] Turanov, A.A., et al. Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem. J. 430:2 (2010), 285–293.
108. [108] Nguyen, P., et al. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 236:2 (2006), 164–174.
109. [109] Grogan, T.M., et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 31:4 (2000), 475–481.
110. [110] Raffel, J., et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142:1 (2003), 46–51.
111. [111] Penney, R.B., Roy, D., Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim. Biophys. Acta: Rev. Cancer 1836:1 (2013), 60–79.
112. [112] Li, C., et al. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget 3:3 (2012), 314–326.
113. [113] Yoo, M.-H., et al. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281:19 (2006), 13005–13008.
114. [114] Sakurai, A., et al. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J. Cell. Physiol. 203:3 (2005), 529–537.
115. [115] Sasada, T., et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 27:5 (1999), 504–514.
116. [116] Kim, N.-H., et al. Antiproliferative effect of gold (I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 46:1 (2013), 59–64.
117. [117] PArK, S.-H., et al. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int. J. Oncol. 45:4 (2014), 1691–1698.
118. [118] Fan, C., et al. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis., 5(4), 2014, e1191.
119. [119] Park, N., Chun, Y.-J., Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J. Toxicol. Environ. Health A 77:22–24 (2014), 1467–1476.
120. [120] You, B.R., Shin, H.R., Park, W.H., PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. Int. J. Oncol. 44:1 (2014), 301–308.
121. [121] Wang, F., et al. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol. Rep. 33:2 (2015), 967–973.
122. [122] Tan, Y., et al. Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide. Int. J. Clin. Exp. Pathol., 7(8), 2014, 4765.
123. [123] Penning, T.M., Drury, J.E., Human aldo–keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464:2 (2007), 241–250.
124. [124] Jin, J., Krishack, P., Cao, D., Role of aldo–keto reductases in development of prostate and breast cancer. Front. Biosci.: J. Virtual Libr. 11 (2005), 2767–2773.
125. [125] Tai, H.-L., et al. Overexpression of aldo–keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol. Rep. 17:2 (2007), 305–312.
126. [126] Laffin, B., Petrash, M., Expression of the aldo–keto reductases AKR1B1 and AKR1B10 in human cancers. Front. Pharmacol., 3, 2012, 104.
127. [127] Yan, R., et al. Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 121:10 (2007), 2301–2306.
128. [128] Penning, T.M., et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo–keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J., 351(Pt 1), 2000, 67.
129. [129] Deng, H.B., et al. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J. Biol. Chem. 277:17 (2002), 15035–15043.
130. [130] Ueda, M., et al. Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol. Oncol. 102:2 (2006), 173–181.
131. [131] Matsunaga, T., et al. Pathophysiological roles of aldo–keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem. Biol. Interact. 202:1 (2013), 234–242.
132. [132] Cui, Y., et al. Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology 9:1–2 (2009), 89–98.
133. [133] Alzeer, S., Ellis, E.M., The role of aldehyde reductase AKR1A1 in the metabolism of gamma-hydroxybutyrate in 1321N1 human astrocytoma cells. Chem. Biol. Interact. 191:1 (2011), 303–307.
134. [134] Liu, J., Wen, G., Cao, D., Aldo–keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat. Anti-cancer Drug Discov. 4:3 (2009), 246–253.
135. [135] Chung, Y.T., et al. Overexpression and oncogenic function of aldo–keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod. Pathol. 25:5 (2012), 758–766.
136. [136] Bai, X., et al. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab. Rev. 48:4 (2016), 541–567.
137. [137] Selga, E., Noé, V., Ciudad, C.J., Transcriptional regulation of aldo–keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem. Pharmacol. 75:2 (2008), 414–426.
138. [138] Matsunaga, T., et al. Involvement of the aldo–keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs 22:5 (2011), 402–408.
139. [139] Huang, K.H., et al. Overexpression of aldo–keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology 57:3 (2010), 384–394.
140. [140] Margis, R., et al. Glutathione peroxidase family – an evolutionary overview. FEBS J. 275:15 (2008), 3959–3970.
141. [141] Chu, F.-F., et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 64:3 (2004), 962–968.
142. [142] Walshe, J., et al. Inactivation of glutathione peroxidase activity contributes to UV-induced squamous cell carcinoma formation. Cancer Res. 67:10 (2007), 4751–4758.
143. [143] Banning, A., Kipp, A., Brigelius-Flohé, R., Glutathione peroxidase 2 and its role in cancer. Selenium, 2011, Springer, 271–282.
144. [144] Florian, S., et al. Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue. Free Radic. Res. 35:6 (2001), 655–663.
145. [145] Mork, H., et al. Inverse mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in colorectal adenomas compared with adjacent normal mucosa. Nutr. Cancer 37:1 (2000), 108–116.
146. [146] Mörk, H., et al. Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus. Int. J. Cancer 105:3 (2003), 300–304.
147. [147] Banning, A., et al. The GI-GPx gene is a target for Nrf2. Mol. Cell. Biol. 25:12 (2005), 4914–4923.
148. [148] Noh, D.-Y., et al. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21:3B (2000), 2085–2090.
149. [149] Chang, J.W., et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 289:2 (2001), 507–512.
150. [150] Yanagawa, T., et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 145:1 (1999), 127–132.
151. [151] Yanagawa, T., et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 156:1 (2000), 27–35.
152. [152] Kim, J.-H., et al. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin. Cancer Res. 13:13 (2007), 3875–3882.
153. [153] Chen, M.-F., et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int. J. Radiat. Oncol. Biol. Phys. 64:2 (2006), 581–591.
154. [154] Sies, H., Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27:9 (1999), 916–921.
155. [155] Tatebe, S., et al. Expression of heavy subunit of γ-glutamylcysteine synthetase (γ-GCSh) in human colorectal carcinoma. Int. J. Cancer 97:1 (2002), 21–27.
156. [156] Soini, Y., et al. Expression of γ-glutamyl cysteine synthetase in nonsmall cell lung carcinoma. Cancer 92:11 (2001), 2911–2919.
157. [157] Seven, A., et al. Breast cancer and benign breast disease patients evaluated in relation to oxidative stress. Cancer Biochem. Biophys. 16:4 (1998), 333–345.
158. [158] Carretero, J., et al. Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clin. Exp. Metastasis, 17(7), 1999, 567.
159. [159] Calvert, P., et al. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 111 (1998), 213–224.
160. [160] Iida, T., et al. Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int. J. Cancer 82:3 (1999), 405–411.
161. [161] Kaur, T., et al. Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma. Dis. Esophagus 21:2 (2008), 103–107.
162. [162] Fujimori, S., et al. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo. Int. J. Oncol. 25 (2004), 413–418.
163. [163] Meister, A., Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51:2 (1991), 155–194.
164. [164] O'Dwyer, P.J., et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14:1 (1996), 249–256.
165. [165] Anderson, C.P., et al. Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp. Cell Res. 246:1 (1999), 183–192.
166. [166] Ross, D., Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36:3–4 (2004), 639–654.
167. [167] Siegel, D., et al. NAD (P) H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65:5 (2004), 1238–1247.
168. [168] Cuendet, M., et al. Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod. 69:3 (2006), 460–463.
169. [169] Long, D.J., et al. NAD (P) H: quinone oxidoreductase 1 deficiency increases susceptibility to benzo (a) pyrene-induced mouse skin carcinogenesis. Cancer Res. 60:21 (2000), 5913–5915.
170. [170] Schlager, J.J., Powis, G., Cytosolic, N.A.D., (P) H:(Quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer 45:3 (1990), 403–409.
171. [171] Mikami, K., et al. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Cancer Sci. 89:9 (1998), 910–915.
172. [172] Matsui, Y., et al. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation. BJU Int. 105:4 (2010), 558–564.
173. [173] Zeekpudsa, P., et al. Suppression of NAD (P) H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. J. Exp. Clin. Cancer Res., 33(1), 2014, 11.
174. [174] Bock, K.W., Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem. Pharmacol. 80:6 (2010), 771–777.
175. [175] Kiang, T.K., Ensom, M.H., Chang, T.K., UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol. Ther. 106:1 (2005), 97–132.
176. [176] Saracino, M.R., Lampe, J.W., Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. Nutrition and cancer 59:2 (2007), 121–141.
177. [177] Cummings, J., et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem. Pharmacol. 67:1 (2004), 31–39.
178. [178] Zahreddine, H.A., Borden, K.L., Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells. Clin. Cancer Res. 21:10 (2015), 2207–2210.
179. [179] Li, M., et al. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. OncoTargets Ther., 7, 2014, 1653.
180. [180] Romero-Lorca, A., et al. Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients. PLOS ONE, 10(7), 2015, e0132269.
181. [181] Hayes, J.D., Flanagan, J.U., Jowsey, I.R., Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 51–88.
182. [182] Hayes, J.D., Pulford, D.J., The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance part II. Crit. Rev. Biochem. Mol. Biol. 30:6 (1995), 521–600.
183. [183] Perera, F.P., et al. Associations between carcinogen–DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians’ Health Cohort Study. Carcinogenesis 23:10 (2002), 1641–1646.
184. [184] Morari, E.C., et al. The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol. Prevent. Biomark. 11:11 (2002), 1485–1488.
185. [185] Kote-Jarai, Z., et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenet. Genomics 11:4 (2001), 325–330.
186. [186] Aktas, D., et al. Glutathione S-transferase M1 gene polymorphism in bladder cancer patients: a marker for invasive bladder cancer?. Cancer Genet. Cytogenet. 125:1 (2001), 1–4.
187. [187] McLellan, L.I., Wolf, C.R., Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist. Updat. 2:3 (1999), 153–164.
188. [188] Schisselbauer, J.C., et al. Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 50:12 (1990), 3562–3568.
189. [189] Noda, E., et al. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepato-gastroenterology 59:113 (2011), 130–133.
190. [190] Ban, N., et al. Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56:15 (1996), 3577–3582.
191. [191] Johansson, K., et al. Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis 28:2 (2006), 465–470.
192. [192] Xu, X., et al. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem. Pharmacol. 92:2 (2014), 220–234.
193. [193] Young, L.C., et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer. Clin. Cancer Res. 7:6 (2001), 1798–1804.
194. [194] Ma, J., et al. Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation. BioMed Res. Int., 2014, 2014.
195. [195] Zaman, G., et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U. S. A. 92:17 (1995), 7690–7694.
196. [196] Shim, G.-s., et al. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic. Biol. Med. 47:11 (2009), 1619–1631.
197. [197] Paumi, C.M., et al. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 276:11 (2001), 7952–7956.
198. [198] Smitherman, P.K., et al. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J. Pharmacol. Exp. Ther. 308:1 (2004), 260–267.
199. [199] Lin, H., et al. Sulforaphane reverses glucocorticoid-induced apoptosis in osteoblastic cells through regulation of the Nrf2 pathway. Drug Des. Dev. Ther., 8, 2014, 973.
200. [200] Das, L., Vinayak, M., Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of NRF2 signalling and modulation of inflammation in prevention of cancer. PLOS ONE, 10(4), 2015, e0124000.
201. [201] Tsai, P.-Y., et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic. Biol. Med. 51:3 (2011), 744–754.
202. [202] Balstad, T.R., et al. Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo – studies in electrophile response element transgenic mice. Mol. Nut. Food Res. 55:2 (2011), 185–197.
203. [203] Gao, A.-M., et al. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34:8 (2013), 1806–1814.